Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Selling 50% of shares @$1.35 (one dollar, thirty five cents

<< Previous

Bullboard Posts

Next >>

Comment by Bigginvestoron Mar 19, 2021 12:11pm

172 Views

Post# 32838305

RE:RE:RE:Selling 50% of shares @$1.35 (one dollar, thirty five cents

PTBailey wrote: I wish and dream of $10, would love to see it obviously but would settle for less to take out my initial investment.

I have 1.3mil so at .25 will sell enough to get out my costs. My average is about .04

those numbers are good . But I'll take it it at .25 or .40 cent's DNT want to be to greedy.

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security